DOCSLIB.ORG

Meibomian Gland Dysfunction Understanding and Implementing the New Consensus Definition and Treatment Regimens Into Your Optometric Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meibomian Gland Dysfunction Understanding and Implementing the New Consensus Definition and Treatment Regimens Into Your Optometric Practice Meibomian Gland Dysfunction Understanding and Implementing the New Consensus Definition and Treatment Regimens Into Your Optometric Practice PROCEEDINGS FROM AN EXPERT PANEL DISCUSSION Course Directors and Co-Chairs Gary N. Foulks, MD, FACS Kelly K. Nichols, OD, MPH, PhD, FAAO Faculty Alan G. Kabat, OD, FAAO Paul M. Karpecki, OD, FAAO Jason J. Nichols, OD, MPH, PhD, FAAO ORIGINAL RELEASE DATE : M AY 2012 | E XPIRATION DATE : M AY 31, 2015 This course is COPE approved for 3 credits. This continuing educational activity is supported by unrestricted COPE Course ID: 34224-AS educational grants from Alcon, Inc; Bausch + Lomb Incorporated; and Santen Pharmaceutical Co, Ltd. Jointly sponsored by the State University of New York College of Optometry Part 2 of 2 Administrator: May 2012 COURSE DIRECTORS FACULTY and CO-CHAIRS Alan G. Kabat, OD, FAAO Associate Professor Gary N. Foulks, MD, FACS College of Optometry Professor Emeritus Nova Southeastern University Department of Ophthalmology & Visual Sciences Fort Lauderdale-Davie, Florida Director of Corneal/External Disease and Refractive Surgery Paul M. Karpecki, OD, FAAO Kentucky Lions Eye Center Clinical Director University of Louisville Corneal Services and Ocular Disease Research Louisville, Kentucky Koffler Vision Group Lexington, Kentucky Kelly K. Nichols, OD, MPH, PhD, FAAO FERV (Foundation for Education and Research Jason J. Nichols, OD, MPH, PhD, FAAO in Vision) Professor Kevin McDaid Vision Source Professor University of Houston College of Optometry College of Optometry University of Houston Houston, Texas Houston, Texas LEARNING METHOD AND MEDIUM Kelly K. Nichols, OD, MPH, PhD, FAAO , has had a financial agreement or affiliation This educational activity consists of a supplement and 30 study questions. The participant during the past year with the following commercial interests in the form of Honoraria/Promotional : should, in order, read the learning objectives contained at the beginning of this supplement, Alcon, Inc; Allergan, Inc; and Inspire Pharmaceuticals, Inc; Consultant/Speaker : Alcon, Inc; read the supplement, answer all questions in the post test, and complete the evaluation form. Allergan, Inc; Bausch + Lomb Incorporated; Celtic Pharma; Forest Laboratories, Inc; ISTA To receive credit for this activity, please follow the instructions provided on the post test and Pharmaceuticals, Inc; InSite Vision Incorporated; Merck & Co, Inc; SARcode Bioscience, Inc; evaluation form. This educational activity should take a maximum of 3.0 hours to complete. and TearLab Corporation; Contracted Research : Alcon, Inc; Inspire Pharmaceuticals, Inc; and TearLab Corporation. CONTENT SOURCE This continuing education (CE) activity is based on a review of the literature and an expert DISCLOSURE ATTESTATION panel discussion. Each of the contributing physicians listed above has attested to the following: 1) that the relationships/affiliations noted will not bias or otherwise influence his or her TARGET AUDIENCE involvement in this activity; This educational activity intends to educate optometrists. 2) that practice recommendations given relevant to the companies with whom he or she has OVERVIEW relationships/affiliations will be supported by the best available evidence or, absent Previously, there had not been a consistent and thorough discussion of meibomian gland evidence, will be consistent with generally accepted medical practice; and anatomy and pathophysiology. An international working group of the Tear Film and Ocular 3) that all reasonable clinical alternatives will be discussed when making practice Surface Society (TFOS) convened and developed a new definition and new terminology on recommendations. meibomian gland dysfunction (MGD), clarifying the differences between it and other ocular surface diseases, and introduced a new diagnosis and management algorithm. This CE OFF-LABEL DISCUSSION monograph captures proceedings from a roundtable discussion of a group of optometrists, This activity includes off-label discussion of azithromycin for MGD, steroids for MGD and some of whom were directly involved in the MGD workshop, others who were not, who for dry eye. gathered to evaluate the clinical relevance of the TFOS MGD Workshop’s findings, particularly as they apply to patients seeking treatment for contact lens-related or general ocular surface PEER REVIEW DISCLOSURES complaints, as well as to those patients cared for before and after ocular surgery. Katherine M. Mastrota, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board : Allergan, Inc; LEARNING OBJECTIVES Bausch + Lomb Incorporated; Focus Laboratories; ISTA Pharmaceuticals, Inc; and Merck Upon completion of this activity, optometrists will be better able to: & Co, Inc; Board Member : Noble Vision Group, LLC; and OCuSOFT, Inc; Ownership • Describe new terminology and classifications of blepharitis and meibomian gland dysfunction Interest : TearLab Corporation. • Distinguish blepharitis/meibomian gland dysfunction from other ocular conditions Leo Semes, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant : Alcon, Inc; Allergan, Inc; and • Describe treatment implications for meibomian gland dysfunction with or without the Merck & Co, Inc; Speaker : Optovue, Inc. presence of additional ocular surface disorders EDITORIAL SUPPORT DISCLOSURES ACCREDITATION DESIGNATION STATEMENT Michelle Dalton, ELS; Cynthia Tornallyay, RD, MBA, CCMEP; and Barbara Lyon This course is COPE approved for 3.0 hours of CE credit. COPE Course ID: 34224-AS. have no relevant commercial relationships to disclose. Check with your local state licensing board to see if this counts toward your CE requirement for relicensure. GRANTOR STATEMENT This continuing educational activity is supported by unrestricted educational grants from DISCLOSURES Alcon, Inc; Bausch + Lomb Incorporated; and Santen Pharmaceutical Co, Ltd. Gary N. Foulks, MD, FACS , has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Honoraria : InSite Vision Incorporated; TO OBTAIN CE CREDIT and Santen Pharmaceutical Co, Ltd; Consultant/Advisory Board : Bausch + Lomb Incorporated; We offer instant certificate processing and support Green CE. Please take this post test and Inspire Pharmaceuticals, Inc; and Scynexis, Inc; Contracted Research : Alcon, Inc. evaluation online by going to www.Mededicus.com and clicking the Educational Alan G. Kabat, OD, FAAO , has had a financial agreement or affiliation during the past Activities & Post Test Center box. Upon passing, you will receive your certificate year with the following commercial interests in the form of Consultant/Advisory Board : Alcon, immediately. You must answer 21 out of 30 questions correctly in order to pass, and may Inc; Essilor of America, Inc; Inspire Pharmaceuticals, Inc; and ISTA Pharmaceuticals, Inc; take the test up to 2 times. Upon registering and successfully completing the post test, your Contracted Research : TearLab Corporation. certificate will be made available online and you can print it or file it. There are no fees for Paul M. Karpecki, OD, FAAO , has had a financial agreement or affiliation during the past participating and receiving CE credit for this activity. year with the following commercial interests in the form of Consultant : Alcon, Inc; Allergan, Inc; Bausch + Lomb Incorporated; Inspire Pharmaceuticals, Inc; ISTA Pharmaceuticals, Inc; and OCuSOFT, Inc. The views and opinions expressed in this educational activity are those of the faculty and do Jason J. Nichols, OD, MPH, PhD, FAAO , has had a financial agreement or affiliation during not necessarily represent the views of the State University of New York College of Optometry; the past year with the following commercial interests in the form of Advisory Board/Speaker : Bausch MedEdicus LLC; Alcon, Inc; Bausch + Lomb Incorporated; Santen Pharmaceutical Co, Ltd; + Lomb Incorporated; and Vistakon; Honoraria/Editorship : Wolters Kluwer; Contracted Research : or Review of Optometry . Please consult products for all approved administration and Alcon, Inc; CIBA VISION Corporation; Inspire Pharmaceuticals, Inc; and Vistakon, Inc. safety information. © 2012 MedEdicus LLC 2 Meibomian Gland Dysfunction: No Longer in the Shadows In the mid 1990s, research in ocular surface disease was in its diseases, proposed a new consensus definition for MGD, and infancy, with disjointed descriptions of patient-reported symptoms introduced a new diagnosis and management algorithm. It was failing to correlate well with clinically observed signs. Terminology the hope of the steering committee to advance the study of MGD was intermingled and not qualified, or sufficiently specific. Around in one large uniform step. To our knowledge, the MGD Workshop the world, clinical studies devised their own sets of inclusion report represents the first time a global consensus has been criteria, limiting the ability to generate consensus. The pathogenic reached on the definition of MGD, and as such, allows a general relationship of dry eye alone or in conjunction with contact lens consensus on how to diagnose and treat patients with MGD. (CL) wear was uncertain. In an important update to a pivotal Previously, there had not been a consistent and thorough report on dry eye published in 1995, 1 the 2007 Dry Eye Workshop discussion of meibomian gland anatomy and pathophysiology.
Load more

Recommended publications
  • Vocabulario De Morfoloxía, Anatomía E Citoloxía Veterinaria
    Vocabulario de Morfoloxía, anatomía e citoloxía veterinaria (galego-español-inglés) Servizo de Normalización Lingüística Universidade de Santiago de Compostela COLECCIÓN VOCABULARIOS TEMÁTICOS N.º 4 SERVIZO DE NORMALIZACIÓN LINGÜÍSTICA Vocabulario de Morfoloxía, anatomía e citoloxía veterinaria (galego-español-inglés) 2008 UNIVERSIDADE DE SANTIAGO DE COMPOSTELA VOCABULARIO de morfoloxía, anatomía e citoloxía veterinaria : (galego-español- inglés) / coordinador Xusto A. Rodríguez Río, Servizo de Normalización Lingüística ; autores Matilde Lombardero Fernández ... [et al.]. – Santiago de Compostela : Universidade de Santiago de Compostela, Servizo de Publicacións e Intercambio Científico, 2008. – 369 p. ; 21 cm. – (Vocabularios temáticos ; 4). - D.L. C 2458-2008. – ISBN 978-84-9887-018-3 1.Medicina �������������������������������������������������������������������������veterinaria-Diccionarios�������������������������������������������������. 2.Galego (Lingua)-Glosarios, vocabularios, etc. políglotas. I.Lombardero Fernández, Matilde. II.Rodríguez Rio, Xusto A. coord. III. Universidade de Santiago de Compostela. Servizo de Normalización Lingüística, coord. IV.Universidade de Santiago de Compostela. Servizo de Publicacións e Intercambio Científico, ed. V.Serie. 591.4(038)=699=60=20 Coordinador Xusto A. Rodríguez Río (Área de Terminoloxía. Servizo de Normalización Lingüística. Universidade de Santiago de Compostela) Autoras/res Matilde Lombardero Fernández (doutora en Veterinaria e profesora do Departamento de Anatomía e Produción Animal.
    [Show full text]
  • Absent Meibomian Glands: a Marker for Eecsyndrome
    ABSENT MEIBOMIAN GLANDS: A MARKER FOR EECSYNDROME ELIZABETH BONNAR, PATRICIA LOGAN and PETER EUSTACE Dublin, Ireland SUMMARY watering eye for the previous week. He gave a A patient with a 20 year history of severe keratocon­ history of continuous attendance at eye clinics in junctivitis of unknown origin was found, on assessment various hospitals since the age of 3 years and was at a blepharitis clinic, to have complete absence of currently attending our own clinic, where he had last meibomian glands. Further examination revealed the been seen 1 month previously. Maintenance medica­ features of EEC syndrome. To our knowledge, this is tion was antiviral ointment and artificial tears. Old the only case to have been diagnosed in this way. The notes were unavailable on admission but there had ocular complications of EEC syndrome and other been a previous spontaneous perforation of the left ectodermal dysplasias are reviewed. cornea at the age of 15 years, and an operation for a blocked tear duct on the right side at the age of 8 The combination of ectrodactyly (lobster claw years. deformity of the hands and feet), ectodermal Vision was 6/18 on the right and hand movements dysplasia (abnormalities of hair, teeth, nails and on the left. There was marked photophobia and sweat glands) and cleft lip and palate, known as EEC tearing on both sides. The left cornea was opacified syndrome, is a rare multiple congenital abnormal­ and vascularised 360°, with central thinning and a ity.1,2 Fewer than 180 cases have been reported in the small perforation just inferonasal to the pupil (Fig.
    [Show full text]
  • Innovations-2019 Copy
    Innovations in Eyecare Paul M. Karpecki, OD, FAAO Kentucky Eye Institute, Lexington KY Gaddie Eye Centers, Louisville KY Retina Associates of KY UPike KY College of Optometry Chief Clinical Editor, Review of Optometry Medical Director, TECP !1 Limbal Stem Cell Deficiency Sequelae Stem Cell – Persistent epithelial defects Technologies – Corneal scarring and ulceration – Conjunctivalization of the cornea – Severe visual loss – Chronic pain – Keratoplasty failure Limbal Stem Cell Transplantation Keratolimbal Allograft Donor Recipient Procedures Donor Autograft – Conjunctival limbal autograft fellow eye Allograft – Living-related conjunctival limbal allograft relative – Keratolimbal allograft cadaver Keratolimbal Allograft RPE Tissue regenerated from Stem Cells S/P Tube Shunt S/P KLAL S/P PK VA 20/30 RPE Tissue Regenerated from ReNeuron’s cryopreserved Pluripotent Skin Stem Cells formulation of retinal stem cell therapy candidate • Cryopreserved formulation of ReNeuron Group’s human retinal progenitor cell therapeutic candidate • From RP in phase II to Rod Cone Dystrophy phase II !14 Stem Cell Coated Contact Lenses • Aniridia patients • Contact lens overwear? • Various ocular surface disease issues: – Steven’s Johnson syndrome – Ocular pemphigoid – GVH – Chemical burns !15 Sensimed Triggerfish lens: Diurnal IOP measurements !17 !18 Glucose Monitoring Contact Lens !19 !20 Yolia Health PROKERA® Class II medical device • Contact lens reshaping comprising of CRYOTEK™ technology after instillation amniotic membrane into a of drops that can alter
    [Show full text]
  • Meibomian Gland Dysfunction, Dropout and Distress: Emerging Therapies
    Eye (2020) 34:1494–1496 https://doi.org/10.1038/s41433-020-0865-5 EDITORIAL Meibomian gland dysfunction, dropout and distress: emerging therapies 1,2 1,2 1,2 Ali Hassan ● Shafi Balal ● Sajjad Ahmad Received: 22 February 2020 / Revised: 26 February 2020 / Accepted: 28 February 2020 / Published online: 8 April 2020 © The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020 Our understanding of the multifactorial origin and com- Conventional management of MGD involves warm eye- plexity of meibomian gland disease (MGD) is evolving lid compresses (increasingly with microwaveable bead-filled rapidly and new treatments are emerging. A recent rando- bags) and systemic antibiotics (oral doxycycline or ery- mised trial comparing lifitegrast ophthalmic solution to thromycin) [6]. However, there are now several new and thermal pulsation for the treatment of inflammatory MGD adjunctive treatment approaches, either as devices or topical/ [1] highlights advances made in treating this frequently systemic therapies: disabling condition. In this editorial, we will describe these emerging therapies (1) Lipiflow is an FDA approved thermal device, which 1234567890();,: 1234567890();,: and any evidence for their use. Disease of the meibomian applies 42.5 °C heat to the palpebral eyelid surfaces glands is commonly encountered in clinical practice [2]. with concurrent proximal to distal peristaltic pressure Mild disease can often be over-diagnosed and over-treated over the meibomian glands. A non-randomised and severe disease, particularly if associated with ocular interventional trial of fifty patients found a single surface inflammatory diseases, can be overlooked or under- Lipiflow treatment to be as effective as a 3-month treated [3].
    [Show full text]
  • Blepharitis and Eyelid Hygiene
    Blepharitis and Eyelid Hygiene You have been informed by your doctor or specialist that you have Blepharitis. Answers to some of the most commonly asked questions are given below. What is Blepharitis? Blepharitis is an inflammatory condition that affects the edges (margins) of the eyelids, and usually causes itching and irritation. It usually affects both eyes and it can occur at any age. Although Blepharitis maybe uncomfortable, it is not a sight threatening condition. What are the symptoms? Blepharitis may cause one or more of the following: Itchiness around the eyes. Persistent irritation or ‘burning’ sensation. Redness and swelling of the eyelid edges. Tiny flakes on the eyelashes. Crusting of the eyelids, especially in the morning. Eyelid cysts / styes. Sensation of ‘grit’ in the eye. Redness of the eye. Symptoms may come and go. It is common to have flare ups or long periods with no symptoms. Scaly Scabs Normal eyelid Eyelid swollen and reddened Bacterial Infection _________________________________________________________________ What are the causes? Blepharitis may be due to a combination of one or more of the following: 0262/05/Sept 2018 - Blepharitis and Eyelid Hygiene Page 1 of 6 A disorder of the Meibomian (oil) Glands at the edge of the eyelid: Normal tears of the eye are made up of three layers - an oily (lipid) layer, a watery (Aqueous) layer and a sticky (mucous) layer. There are Meibomian glands inside the eyelids with openings onto the edges of the eyelids (lid margins) which naturally produce oil. This oil stops the watery element of the tear film from drying out. At times the Meibomian glands become blocked; this leads to the tear film breaking down and ‘evaporative’ dry eyes.
    [Show full text]
  • Meibomian Gland Dysfunction: an Overlooked Eyelid Disease
    Advances in Ophthalmology & Visual System Review Article Open Access Meibomian gland dysfunction: an overlooked eyelid disease Abstract Volume 8 Issue 3 - 2018 Meibomian gland dysfunction is a multifactorial and chronic disease of the eyelids, Burak Turgut,1 Onur Çatak,2 Tamer Demir3 leading to eye irritation, inflammation, evaporative and aqueous-deficient dry eye 1Department of Ophthalmology, Yuksek Ihtisas University, Turkey and negatively affecting the quality of life. MGD is often overlooked clinically. This 2 review presents a general and practical guide for MGD diagnosis and management. Department of Ophthalmology, Firat University, Turkey 3Department of Ophthalmology, Onsekiz Mart University, Keywords: Meibomian gland, dysfunction, dry eye, hypersecretory, hyposecretory, Turkey duct obstruction, lipid layer, tear film, ocular surface diseaset Correspondence: Burak Turgut, Private Etimed Hospital, Ophthalmology Clinic, Elvan Mah. 1934. Sok. No:4 Etimesgut/ANKARA, Turkey, Tel +90 (312) 293 06 06, Email [email protected] Received: May 21, 2018 | Published: May 29, 2018 Introduction evaporative dry eye and also the most common underlying pathology in the cases with the aqueous-deficient dry eye. Additionally, MGD Meibomian glands (MGs) are large sebaceous glands, vertically can negatively affect the quality of life.2–9 arranged in the tarsal plates of the upper and lower eyelids and produce the lipids of the outermost layer of the preocular tear film. Risk factors The tarsal glands are firstly described by Heinrich MEIBOM (1638- The risk factors for MGD identified by the epidemiology and risk 1700), a professor of medicine at the university town of Helmsted, factors identification committee of International Meibomian Gland and afterward, these glands were called as MGs.1 Dysfunction Study group are divided into three group as ophthalmic, Definition systemic and therapeutic (Table 1).
    [Show full text]
  • Embryologic and Fetal Development of the Human Eyelid
    MAJOR REVIEW Embryologic and Fetal Development of the Human Eyelid Hatem A. Tawfik, M.D.*, Mohamed H. Abdulhafez, F.R.C.S.*, Yousef A. Fouad, M.B.B.S.‡, and Jonathan J. Dutton, M.D., Ph.D., F.A.C.S.† *Department of Oculoplastic Surgery, Watany Eye Hospital, Cairo, Egypt; †Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A.; and ‡Department of Ophthalmology, Ain Shams University, Cairo, Egypt were usually focused on development during the embryonic Purpose: To review the recent data about eyelid rather than the fetal period. But some newer more comprehen- morphogenesis, and outline a timeline for eyelid development sive cadaver studies are now available, and dozens of recent from the very early stages during embryonic life till final articles document the molecular basis of eyelid development. maturation of the eyelid late in fetal life. Reviewing the literature spanning almost a century is confusing Methods: The authors extensively review major studies because some authors only referred to Carnegie stages, others detailing human embryologic and fetal eyelid morphogenesis. liberally interchanged gestational age with postfertilization age, These studies span almost a century and include some more and some researchers used the crown-rump length measure- recent cadaver studies. Numerous studies in the murine model ments to determine the embryonic stage and fetal age, which have helped to better understand the molecular signals that may not be a very reliable measure after the 84 mm cutoff point govern eyelid embryogenesis. The authors summarize the current set by some obstetricians.2 Other authors discussed the time- findings in molecular biology, and highlight the most significant line of eyelid development in terms of weeks or months with- studies in mice regarding the multiple and interacting signaling out specifying how the age was estimated.
    [Show full text]
  • Meibomian Gland Dysfunction, Dry Eye Disease, and Unhappy Cataract Surgery Patients
    s THE LITERATURE MEIBOMIAN GLAND DYSFUNCTION, DRY EYE DISEASE, AND UNHAPPY CATARACT SURGERY PATIENTS Parameters of meibomian gland dysfunction predict persistent postoperative dry eye symptoms and are prevalent in a large percentage of patients presenting for cataract surgery. BY STEVEN L. MASKIN, MD; AND ERIN L. GREENBERG, MD PERIOPERATIVE OCULAR PARAMETERS ASSOCIATED WITH DISCUSSION PERSISTENT DRY EYE SYMPTOMS AFTER CATARACT SURGERY After cataract surgery, an excellent postoperative visual outcome can be overshadowed by DED symptoms, Choi YJ, Park SY, Jun I, et al1 including ocular irritation and transiently blurred vision. These problems can be attributed to alterations of the ABSTRACT SUMMARY ocular surface during phacoemulsification.2 Although Choi and colleagues evaluated perioperative dry eye most of these alterations are thought to be transient, disease (DED) and meibomian gland dysfunction (MGD) Choi et al showed that persistent symptoms are signifi- parameters and their association with persistent symptoms cantly associated with low TBUT and MG orifice obstruc- after phacoemulsification with IOL implantation. The study tion scores3 and with increased MG dropout at 1 month included 116 eyes of 116 patients who underwent uncom- after surgery. To identify patients at risk of persistent plicated cataract surgery and who had no history of ocular DED symptoms preoperatively (and thereby allow ear- comorbidity or use of topical eye drops other than artificial lier treatment), the investigators performed regression tears. Parameters including lipid layer thick- ness, meibomian gland (MG) dropout, tear breakup time (TBUT), Oxford staining score, lid margin abnormality, meibum quality, STUDY IN BRIEF meibum expressability, orifice obstruction, s Researchers evaluated the association of perioperative dry eye disease (DED) and MGD stage, Ocular Surface Disease Index meibomian gland dysfunction (MGD) parameters with persistent DED symptoms (OSDI) score, and Schirmer test result were after phacoemulsification.
    [Show full text]
  • Índice De Denominacións Españolas
    VOCABULARIO Índice de denominacións españolas 255 VOCABULARIO 256 VOCABULARIO agente tensioactivo pulmonar, 2441 A agranulocito, 32 abaxial, 3 agujero aórtico, 1317 abertura pupilar, 6 agujero de la vena cava, 1178 abierto de atrás, 4 agujero dental inferior, 1179 abierto de delante, 5 agujero magno, 1182 ablación, 1717 agujero mandibular, 1179 abomaso, 7 agujero mentoniano, 1180 acetábulo, 10 agujero obturado, 1181 ácido biliar, 11 agujero occipital, 1182 ácido desoxirribonucleico, 12 agujero oval, 1183 ácido desoxirribonucleico agujero sacro, 1184 nucleosómico, 28 agujero vertebral, 1185 ácido nucleico, 13 aire, 1560 ácido ribonucleico, 14 ala, 1 ácido ribonucleico mensajero, 167 ala de la nariz, 2 ácido ribonucleico ribosómico, 168 alantoamnios, 33 acino hepático, 15 alantoides, 34 acorne, 16 albardado, 35 acostarse, 850 albugínea, 2574 acromático, 17 aldosterona, 36 acromatina, 18 almohadilla, 38 acromion, 19 almohadilla carpiana, 39 acrosoma, 20 almohadilla córnea, 40 ACTH, 1335 almohadilla dental, 41 actina, 21 almohadilla dentaria, 41 actina F, 22 almohadilla digital, 42 actina G, 23 almohadilla metacarpiana, 43 actitud, 24 almohadilla metatarsiana, 44 acueducto cerebral, 25 almohadilla tarsiana, 45 acueducto de Silvio, 25 alocórtex, 46 acueducto mesencefálico, 25 alto de cola, 2260 adamantoblasto, 59 altura a la punta de la espalda, 56 adenohipófisis, 26 altura anterior de la espalda, 56 ADH, 1336 altura del esternón, 47 adipocito, 27 altura del pecho, 48 ADN, 12 altura del tórax, 48 ADN nucleosómico, 28 alunarado, 49 ADNn, 28
    [Show full text]
  • Meibomian Gland Dysfunction Leaflet
    Meibomian gland dysfunction Meibomian gland dysfunction (MGD) is when the eyelid glands don’t produce enough oil to stop the watery layer of the tears from drying out. What is meibomian gland dysfunction? Symptoms The normal tears of the eye are made up of The eyelids can become sore and swollen three layers – an oily (lipid) layer, a watery as the glands become blocked. As the eyes (aqueous) layer, and a sticky (mucous) layer. become dry, they can feel itchy or gritty, as if MGD is when the glands that make the oily there’s something in the eye. The eyes may be layer of the tears are not working properly red, and if they’re sore, may be watery, which and this allows the watery layer of the tears to can cause vision to become blurry. dry out. Treatment The meibomian glands are inside the eyelids, Treatment involves releasing the oily tears from and the openings are on the edge of the the glands using hot compresses. You need eyelids. The outer oily layer stops the watery to get a face cloth, or cotton pads, soak them layer of the tears from drying out. When the in hot (not boiling) water, close your eyes, and glands become blocked, the oily part of the hold the hot cloth onto your eyelids. Wet the tears cannot be released. This causes the cloth again with hot water and keep applying watery tears to dry up more quickly which the compress for at least five minutes. Repeat results in the eye becoming dry and can every day until the condition gets better.
    [Show full text]
  • Primary Intraepithelial Sebaceous Gland Carcinoma of the Palpebral Conjunctiva
    CLINICOPATHOLOGIC REPORT SECTION EDITOR: W. RICHARD GREEN, MD Primary Intraepithelial Sebaceous Gland Carcinoma of the Palpebral Conjunctiva Santosh G. Honavar, MD; Carol L. Shields, MD; Marlon Maus, MD; Jerry A. Shields, MD; Hakan Demirci, MD; Ralph C. Eagle, Jr, MD ebaceous gland carcinoma usually arises from meibomian or Zeis glands deep within the eyelid, but it can rarely arise within the conjunctival epithelium without a deep com- ponent. We describe a woman with a history of chronic blepharoconjunctivitis unre- sponsive to topical medications. Examination disclosed confluent papillary hypertro- phyS of the upper palpebral conjunctiva and deposits of white flaky material. Tarsoconjunctival punch biopsy revealed intraepithelial sebaceous gland carcinoma. Management consisted of frozen section– controlled complete tumor excision with removal of the entire posterior lamella of the right upper eyelid, cryotherapy to the margins, and reconstruction. Histopathologic analysis confirmed pri- mary sebaceous gland carcinoma localized to the conjunctival epithelium without involvement of underlying meibomian or Zeis glands or the caruncle. Patients with unexplained chronic unilat- eral blepharoconjunctivitis or papillary hypertrophy of the palpebral conjunctiva should be con- sidered for biopsy to rule out neoplasia, even when there is no sign of an underlying eyelid mass. Arch Ophthalmol. 2001;119:764-767 Sebaceous gland carcinoma of the ocular fined to and presumably arising primar- adnexa is a relatively rare tumor that arises ily within the conjunctival epithelium from the meibomian glands, Zeis glands, without underlying glandular or invasive or sebaceous glands in the caruncle or eye- component is uncommon.8-10 Herein, we brow.1-7 It is estimated that this cancer rep- describe one such case with supportive resents 1% to 6% of all eyelid malignant histopathologic findings.
    [Show full text]
  • Meibomian Gland Dysfunction (MGD) Patient Information Information and Advice to Help You Understand and Manage Your Condition
    Meibomian Gland Dysfunction (MGD) Patient Information Information and advice to help you understand and manage your condition The information in this leaflet has been developed by Scope Health Inc. in collaboration with leading Eye Doctors. MGD You have been diagnosed The surface of your eye is covered by a thin layer of tears, called with Meibomian Gland the Tear Film. Your Tear Film has several important functions; it washes, protects, nourishes and lubricates the eye. Dysfunction (MGD), a chronic condition which Blinking smooths the Tear Film evenly across the surface occurs when the glands of the eye and stimulates the production of tears. in the eyelids don’t produce Tears are produced by several systems, and if any part enough oil, or the oil that is of these systems break down, it can result in a reduced produced is of poor quality. quality or quantity of tears. This oil is called Meibum. The lipid (oily) layer of the Tear Film is very important. It It protects the watery layer is produced by the Meibomian glands in the eyelids. If the of tears which cover your lipid layer is not present or is of poor quality in the Tear Film, eye eyes and prevents them from problems can result. drying out. 2 The Tear Film MUCIN LAYER AQUEOUS LIPID allows the water (WATER) LAYER (OIL) LAYER layer to spread nourishes lubricates evenly over the and protects and prevents surface of the eye the eye evaporation 3 Symptoms and causes If you have MGD, you may suffer from some or all of the following: Watery eyes Burning or gritty sensation in the eyes Sore, red, inflamed eyelids Eyelids that are difficult to open in the mornings Light sensitivity Dandruff around the eyelids Fluctuations in vision Contact lens discomfort 4 What are the possible causes of MGD? MGD occurs when the Meibomian glands (which make the oily layer of the Tear Film), are not working properly and become clogged.
    [Show full text]